Document Detail

Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.
MedLine Citation:
PMID:  15998959     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Adverse events associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) have led to the publication of Canadian prescription guidelines. Prescription practices following the publication of these guidelines and the introduction of COX-2 inhibitors in the Quebec formulary of reimbursed medications remain largely unexplored. OBJECTIVES: To compare the prevalence of contra-indications and selected risk factors for NSAID-toxicity among COX-2 inhibitor users and non-selective NSAID users. METHODS: A case-control analysis was conducted in a random sample of Quebec adult drug plan members who were treated with celecoxib (n=42,422 cases), rofecoxib (n=25,674 cases), full-dose (anti-inflammatory doses) of non-selective NSAIDs (n=9,673 cases), or low-dose NSAIDs (n=2,745 controls) in the year 2000. Data were obtained from the Quebec prescription and medical services databases (RAMQ). RESULTS: Patients with a history of gastropathy were more likely to be prescribed COX-2 inhibitors than low-dose NSAIDs; the odds ratios were 1.73 (95%CI: 1.56-1.91) and 1.49 (1.33-1.66), respectively for celecoxib and rofecoxib. Corresponding results for concomitant use of anticoagulants were 1.95 (1.34-2.83) for celecoxib and 1.87 (1.26-2.77) for rofecoxib, and for use of corticosteroids they were 1.29 (1.08-1.54) and 1.23 (1.01-1.49). Conversely, patients with the following characteristics were less likely to receive COX-2 inhibitors than low-dose non-selective NSAIDs: age 75+ (OR=0.64; 0.56-0.72 for celecoxib, OR=0.48; 0.76-0.99 for rofecoxib), hypertension (OR=0.83; 0.75-0.92 for celecoxib, OR=0.87; 0.77-0.97 for rofecoxib), and concomitant use of diuretics (OR=0.72; 0.63-0.82 for celecoxib; OR=0.77; 0.66-0.89 for rofecoxib). CONCLUSION: Patients with risk factors for NSAID gastropathy were more likely prescribed COX-2 inhibitors, while the presence of other contra-indications led to the prescription of low-dose non-selective NSAIDs. However, 12.7% of users of full-dose non-selective NSAIDs were age 75+ and 12.0% had a history of gastropathy, which are considered important risk factors for adverse events.
Yola Moride; Thierry Ducruet; Jean-François Boivin; Frédéric Lavoie; Sophie Rochon
Related Documents :
20070439 - Nsaids inhibit in vitro msc chondrogenesis but not osteogenesis: implications for mecha...
7834159 - Nsaid-related adverse drug interactions with clinical relevance. an update.
3625669 - Nonsteroidal antiinflammatory drugs and articular cartilage.
15276689 - Isobolographic analysis of interaction between cyclooxygenase inhibitors and tramadol i...
10203429 - The epidemiology of nonsteroidal anti-inflammatory drugs.
15481999 - Management of acute and chronic gouty arthritis: present state-of-the-art.
16893619 - Microencapsulation of drugs by electro-hydro-dynamic atomization.
3245229 - The metabolism and disposition of 14c-indolidan, a potent and orally active cardiotonic...
11711509 - Blood pressure responses to small doses of amiloride and spironolactone in normotensive...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2005-06-17
Journal Detail:
Title:  The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique     Volume:  12     ISSN:  1710-6222     ISO Abbreviation:  Can J Clin Pharmacol     Publication Date:  2005  
Date Detail:
Created Date:  2005-07-06     Completed Date:  2006-02-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9804162     Medline TA:  Can J Clin Pharmacol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  e201-11     Citation Subset:  IM    
Faculty of Pharmacy, Université de Montréal, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage,  adverse effects*,  contraindications
Case-Control Studies
Cyclooxygenase Inhibitors / administration & dosage,  adverse effects*,  contraindications
Guideline Adherence
Health Status
Insurance, Pharmaceutical Services
Middle Aged
Practice Guidelines as Topic*
Risk Factors
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Cyclooxygenase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Use of physician profiles to influence prescribing of topical corticosteroids.
Next Document:  Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP)...